Cholesterol, statins and dementia

Current Opinion in Lipidology

Volumn 15, Issue 6, 2004, Pages 667-672

  Wolozin, Benjamin ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; secretase; ABCA1; Amyloid precursor protein; Apolipoprotein E; LDL related receptor protein; LRP1 LXR; Presenilin

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; CARRIER PROTEIN; CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PRESENILIN; PROTEIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DEMENTIA; ENZYME ACTIVITY; GENETICS; HUMAN; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CHOLESTEROL; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

ANIMALIA;

EID: 10044283187     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200412000-00007     Document Type: Review

References (34)

1. Wahrle SE, Jiang H, Parsadanian M, et al. ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 2004; 279:40987-40993. A very interesting study that provides important insights into the mechanisms underlying cholesterol secretion in the brain.
2. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108:779-784. An excellent review of a protein with complex functions. Although LRP is identified as a lipoprotein receptor, it also contributes to a number of signal transduction cascades.
3. Lai EC. Lipid rafts make for slippery platforms. J Cell Biol 2003; 162:365-370. This review broadly covers the many areas of cell biology that are dependent on lipid rafts.
4. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72:137-174. This is an authoritative, detailed review of the many enzymes that control bile acid synthesis by the individual who cloned many of these enzymes.
5. Sanchez L, Alvarez V, Gonzalez P, et al. Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am J Med Genet 2001; 105:76-78.
6. Kolsch H, Ptok U, Mohamed I, et al. Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. Am J Med Genet 2003; 1218:128-130.
7. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003; 60:29-35. This study provides a detailed analysis that relates pathology, risk and polymorphisms very elegantly.
8. Reitz C, Tang MX, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61:705-714.
9. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137:149-155. This provocative article stands out in contrast to the many negative studies searching for an association between serum cholesterol and Alzheimer's disease.
10. Teunissen CE, De Vente J, von Bergmann K, et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 2003; 24:147-155. This is a very detailed study of changes in serum sterols that is highly informative.
11. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces Alzheimer's disease Aβ42 and Aβ40 levels in vitro and in vivo. PNAS 2001; 98:5856-5861.
12. Cordy JM, Hussain I, Dingwall C, et al. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100:11735-11740. This is an elegant article that uses molecular approaches to prove that β-secretase activity increases in cholesterol-rich membrane environments.
13. Wada S, Morishima-Kawashima M, Qi Y, et al. Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 2003; 42:13977-13986.
14. Burns M, Gaynor K, Olm V, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci 2003; 23:5645-5649.
15. Pietrzik CU, Yoon IS, Jaeger S, et al. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 2004; 24:4259-4265. This is a very thorough article that presents a clear picture about how APP binding proteins regulate APP processing.
16. Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003; 24:637-643. This is a surprising article that has very important implications for the field.
17. Friedhoff LT, Cullen EI, Geoghagen NS, et al. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (Abeta) peptide. Int J Neuropsychopharmacol 2001; 4:127-130.
18. Hoglund K, Wiklund O, Vanderstichele H, et al. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004; 61:333-337.
19. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 2003; 60:510-515. This clinical article compares the actions of different statins, and comes up with the surprising result that the statins inhibit oxysterol production with equipotency, despite apparent differences in their ability to penetrate the blood-brain barrier.
20. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57:1439-1443.
21. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356:1627-1631.
22. Zandi P, Sparks L, Khachaturian A, et al. Do statins reduce risk of incident dementia and AD? The Cache County Study. Arch Gen Psychiatry 2004 (in press).
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
25. Zacco A, Togo J, Spence K, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003; 23:11104-11111. This article furthers the emerging story indicating that statins act as effective neuroprotective agents.
26. Lu D, Goussev A, Chen J, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004; 21:21-32.
27. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52:346-350.
28. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
29. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003; 144:681-692.
30. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78-84.
31. Sun Y, Yao J, Kim TW, et al. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 2003; 278:27688-27694. This is an elegant article that demonstrates that LXR inhibits β-amyloid production through a mechanism mediated in part by ABCA1.
32. Brown J, Theisler C, Silberman S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 2004; 279:34674-34681. This article covers the pharmacological effects of the naturally occurring oxysterol, and also examines the pathology of Cyp46, the enzyme that produces 24(S)-hydroxycholesterol.
33. Lund EG, Xie C, Kotti T, et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003; 278:22980-22988.
34. Puglielli L, Konopka G, Pack-Chung E, et al. acyl-Coenzyme A: cholesterol acyltransferase (ACAT) modulates the generation of the amyloid b-peptide. Nat Cell Biol 2001; 3:905-912.